new drugs, we have been increasing the global R&D capabilities by establishing research centers in India, China, and the United States. In virtue of our major products including URSA, Daewoong’s growth potential was recognized and for the first time in Korean pharmaceutical industry, we were selected for the ‘World Class 300 project’ in 2012, a government supported global business development project. We were also selected as ‘Innovative Pharmaceutical Company’ by the government in 2012, for investing more than 10% of our sales into R&D. ◦ Product Portfolio No Classifi- cation Section (Bio/Synthesis) Product Name Main Ingredient Use (Indications) Formulation Date of Sales 1 IMD Comb. Olostar Olmesartan Rosuvastatin Hypertension Dyslipidemia Tablet 2014 2 Bio-similar Bio Eposis Erythropoietin anemia Injection 3 Bio-similar Bio Caretropin Somatropin growth hormone deficiency Injection 4 Bio Bio Nabota Botulinum toxin type A glabellar lines Injection 2014 5 NCE Bio Easyef Epidermal growth factor diabetic foot ulder Spray 2001 6 NCE Comb. URSA Ursodeoxycholic acid (UDCA) Liver disease Tablet/ Capsule 1986 7 IMD Comb. Albis Ranitidine Bismuth Sucralfate Gastroenterology Tablet 2000 8 IMD Comb. Smecta Dioctahedral smectite Diarrhea Suspension 9 Branded Generic Comb. Luphere Leuprolide acetate prostate cancer, endometriosis, breast cancer Injection 2005 ◦ R&D Pipeline No Classifi- cation Section (Bio/Synthesis) Name of Technology Main Ingredient (Description) Use (Indications) Stage of Development 1 IMD Small Molecule CV Fixed-dose Combination Chemical Hyperlipidemia/ Hypertension Approved 2 Bio-similar Bio Recombinant human erythropoietin α Bio Anemia of CRF Marketed 3 Bio-similar Bio Recombinant human growth hormone Bio Deficiency of HGH Marketed 4 New Drug Biologics Epidermal Growth Factor EGF Diabetic Foot Ulcer Marketed 5 Bio convergence Others Alveolar Bone Regeneration BMP-2 Bone Formation Approved
6 Bio convergence Others Spinal Fusion BMP-2 Bone Formation Phase III 7 IMD Small Molecule Nurigra Chewable Tablet Sildenafil Citrate Erectile Dysfunction Marketed 8 IMD Small Molecule MEGAVEC 400MG Imatinib Leukemia Marketed 9 Branded Generic Semi Synthesis UDCA High Purity Ursodeoxycholic Acid PBC Marketed 10 Branded Generic Small Molecule Sustained Release of Leuprolide Leuprolide Acetate Cancer Marketed ◦ GMP Certifications No Product Name Active Ingredient Indication Status 1 Eposis Recombinant human erythropoietin α Anemia of CRF Certified: Vietnam, Philippines, Thailand/ Ongoing: Sri Lanka, Turkey 2 Caretropin Somatropin Deficiency of HGH Certified: Vietnam/ Ongoing: Ukraine, Iran, Uruguay, Philippines, Indonesia, Thailand, Pakistan 3 Ursa Ursodeoxycholic Acid PBC/Gallstone Certified: Vietnam, Thailand, Philippines, 4 Ursa Ursodeoxycholic Acid Liver Function Disorder SFDA 5 Leuprolide Prostate Cancer Endometriosis Certified: Vietnam, Philippines, Nigeria Ongoing: Russia Minzdrav Authoriazation, Mexico, Thailand 6 Meropenem Meropenem Antibioti20/5 tabs ANDA 7 Olosta Olmesartan /Rosuvastatin Hypertension /Hyperlipidemia Ongoing registration for SFDA Approval 8 Nabota Clostridium Botulinum Toxin A Glabbler Line Ongoing registration for Thailand Approval 9 Easyef Nepidermin Diabetic Foot Ulcer Authorization Vietnam, Thailand, Ongoing registration more than 20 coutries including Turkey, Russia ◦ Contact Information Name Eunsun Yang Position Manager Email esyang365@daewoong.co.kr Phone 82-2-550-8452
Dry syr. 13 Process improvement Synthesis Penzal Q Caffeine anhydrous, Acetaminophen, Ethenzamide Pain & fever Tab. 14 Process improvement Synthesis Belotaxel Docetaxel Breast cancer, Non-small cell lung cancer, Prostate cancer, Ovarian cancer, Head and neck cancer, Gastric cancer, Esophagus cancer Inj. 15 Process improvement Synthesis Belloxa Oxaliplatin Colorectal cancer, Gastric cancer Inj. 16 Process improvement Synthesis Gemtan Gemcitabine Non-small cell lung cancer, Pancreatic cancer, Bladder cancer, Breast cancer, Ovarian cancer, Biliary cancer Inj. 17 Process improvement Synthesis Sokchung Cinnamon bark ext., Citrus unshiu peel etc indigestion Sol. 18 Process improvement Synthesis OMP omeprazole Peptic ulcer disease Tab. 19 Process improvement Synthesis Amoxapen Amoxicillin Antibiotics (Penicillins) Cap., Tab., Dry syr. 20 Process improvement Synthesis Itun Q Titrated extract of zea may L. unsaponifiable fraction periodontal disease Tab. 21 Process improvement Synthesis Modcol Acetaminophen etc. Cold Syr. 22 Process improvement Synthesis Deilatren carvedilol Hypertension Etc. Cap. 23 Process improvement Synthesis Imotun avocado-soya unsaponifiables degenerative arthritis, periodontal disease Cap. Producst Name Active Ingredient Indication Categories Expected Country TacroBell Tacrolimus Immunosuppressant Prescription Medicine Worldwide Duvie Lobeglitazone Anti-diabetics Prescription Medicine Worldwide Telminuvo Telmisartan+ S-amlodipine Anti-hypertension Prescription Medicine Worldwide Leukivec Imatinib Anti-cancer Prescription Medicine Worldwide Gemtan Gemcitabine Anti-cancer Prescription Medicine Worldwide
CEO Chairman Huh, Il Sup Vice chairman Cho, Soon Tae President Rhee, Byung Geon President Huh, Eun Chul Business Manufacturing and sales of medicine and medical supplies, etc. ◦ Product Portfolio I.V.-Globulin SN inj. Including high purity IgG immune function improved formulation Hunterase (Hunter syndrome drug) Shinbaro : For the treatment(Enzyme Replacement Therapy) of Hunter syndrome (Mucopolysaccharidosis II) Shinbaro (Osteoarthritis) Urokinase-GCC inj. Cerebral I.V. Hepabig inj. GreenGene F inj. 500I.U. Hemophilia A patients with bleeding symptom control and hemostasis Green Gene inj. Hemophilia A patients with drug Japanese Encephalitis Vaccine-GCC inj. Prevention of Japanese encephalitis GC FLU pre-filled syringe inj. Prevention of influenza (flu) Varicella Vaccine-GCC inj. For prophylaxis of Varicella Varicella-Zoster Immune inj. Passive immunization against chickenpox formulation Sero-Tet Circulation Authority Executive Summary Hepabig inj. Hepatitis B vaccination Albumin inj. 20%-GCC: Hypoalbuminemia drug ◦ Company Milestones Year 1971 Produced the nation’s first plasma fractionation droduct. 1983 Developed Hepavax B, the world’s 3rd Hepatitis B vaccine. 1990 Established the Korea Hemophilia Foundation. 1993 Developed the world’s 2nd varicella vaccine. 1995 Established Green Cross China. 2008 Developed GreenGene, the world’s 4th recombinant Factor Ⅶ for hemophilia A. 2009 Established Green Cross America(GCAM). 2012 Developed Hunterase, the world’s 2nd treatment for Hunter syndrome. 2013 Signed a contract with the Thai Red Cross for plasma fractionation plant project.